<DOC>
	<DOCNO>NCT00357708</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat decitabine treat patient relapse , refractory , poor-prognosis hematologic cancer disease . Vorinostat may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , decitabine , work different way stop growth cancer cell , either kill cell stop divide . Giving vorinostat together decitabine may kill cancer cell</brief_summary>
	<brief_title>Vorinostat Decitabine Treating Patients With Relapsed , Refractory , Poor-Prognosis Hematologic Cancer Other Diseases</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximal tolerate dose ( MTD ) dose limit toxicity ( DLT ) vorinostat combination Decitabine patient relapsed/refractory poor prognosis acute myelogenous leukemia ( AML ) , acute lymphocytic leukemia ( ALL ) , myelodysplastic syndrome ( MDS ) chronic myeloid leukemia accelerate blastic phase ( CML-BP ) . 1.2 To describe clinical activity combination Decitabine vorinostat patient population . 1.3 To determine vivo molecular effect combination . This include measure effect DNA methylation , histone H3 H4 acetylation change gene expression . 1.4 To determine pharmacokinetic characteristic combination . OUTLINE : This dose-escalation study . Patients receive decitabine IV 1 hour day 1-5 oral vorinostat ( SAHA ) three time daily day 6-19 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos decitabine SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient treat dose . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients must histologically confirm acute myelogenous leukemia ( AML ) , acute lymphocytic leukemia ( ALL ) , chronic myelogenous leukemia ( CML ) , myelodysplastic syndrome ( MDS ) myeloproliferative disease ( MPD ) Patients refractory relapse acute myelogenous leukemia ( AML ) , acute lymphocytic leukemia ( ALL ) , chronic myelogenous leukemia ( CML ) , myelodysplastic syndrome ( MDS ) IPSS intermediate 1 myeloproliferative disease ( MPD ) consider study ; patient CML eligible document hematologic resistance imatinib mesylate , lack cytogenetic response imatinib mesylate 12 month therapy ; patient Chronic Myelomonocytic Leukemia ( CMML ) Philadelphia negative CML eligible disease control standard therapy ( e.g . hydroxyurea ) show sign disease progression standard therapy ( blast count &gt; 5 % , platelet count &lt; 100K ) ; patient Acute Promyelocytic Leukemia eligible progressed standard chemotherapy , ATRA well Arsenic Trioxide therapy ; untreated patient older 60 year age AML ( except APL ) MDS IPSS intermediate 1 , eligible standard therapy , also eligible Patients must chemotherapy 2 week ( six week nitrosoureas mitomycin C ) prior enter study recover toxic effect therapy unless evidence rapidly progressive disease ; evidence rapidly progressive disease , use hydroxyurea allow prior start clinical trial first cycle therapy ; histone deacetylase inhibitor , include valproic acid , stop 2 week prior enter study Life expectancy great 8 week ECOG performance status 02 Total bilirubin = &lt; 2 mg/dL AST ( SGOT ) ALT ( SGPT ) = &lt; 2.5 X institutional upper limit normal Creatinine = &lt; 2 mg/dL Cardiac ejection fraction &gt; = 50 % Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients may receive investigational agent Patients clinical evidence CNS disease exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event History allergic reaction attribute compound similar chemical biologic composition vorinostat decitabine Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated vorinostat HIVpositive patient receive combination antiretroviral therapy ineligible Vorinostat take concomitantly HDAC inhibitor compound HDAC inhibitor like activity , valproic acid ; patient receive agent antitumor therapy enroll vorinostat oncology trial ; patient receive agent indication , e.g . epilepsy , may enroll vorinostat trial 30 day washout period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>